Impact of nurse case manager-pharmacist collaboration on adverse-drug-event reporting

American Journal of Health-System Pharmacy

Volumn 61, Issue 5, 2004, Pages 483-487

  Lata, Paul F ^a   Mainhardt, Marianne ^b   Johnson, Curtis A ^c  

^a Bay Area Medical Center ^*  (United States)

^b NE Wisconsin Technical College ^*  (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ARTICLE; CLINICAL PROTOCOL; COMPUTER SYSTEM; COST CONTROL; DIARRHEA; DISABILITY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG UTILIZATION; EDUCATION PROGRAM; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITAL PERSONNEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; LENGTH OF STAY; MANAGER; MEDICAL DOCUMENTATION; MEDICAL RECORD; MEDICATION ERROR; MENTAL DISEASE; NAUSEA AND VOMITING; NURSE; PATIENT CARE; PATIENT COMPLIANCE; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; PROFESSIONAL PRACTICE; RIGOR; RISK ASSESSMENT; RISK FACTOR; SKILL; TECHNIQUE;

EID: 1542317787     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.5.483     Document Type: Article

References (31)

1. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993; 8:289-94.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-5.
3. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-6.
4. Winterstein AG, Sauer BC, Hepler CD et al. Preventable drug-related hospital admissions. Ann Pharmacother. 2002; 36: 1238-48.
5. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002; 36:1331-6.
6. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11.
7. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001; 41:192-9.
8. Leape LL, Brennan TA, Laird N et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
9. Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995; 274:29-34.
10. Schneider PJ. Workshop summaries. Am J Health-Syst Pharm. 2002; 59:2333-6.
11. Jha AK, Kuperman GJ, Teich JM. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998; 5:305-14.
12. Classen DC, Pestotnik SL, Evans RS et al. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991; 266:2847-51.
13. Cullen DJ, Bates DW, Small SD et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. It Comm J Qual Improv. 1995; 21:541-8.
14. Morrison-Griffiths S, Pirmohamed M. Specialist nurse reporting of adverse drug reactions. Prof Nurse. 2000; 15: 300-4.
15. Herrera CR, Moss JT, Reves RR et al. Feasibility study of surveying the adverse drug reaction surveillance systems in a large community of hospitals. Ann Pharmacother. 1992; 26:384-91.
16. O'Neil AC, Petersen LA, Cook EF et al. Physician reporting compared with medical-record review to identify adverse medical events. Ann Intern Med. 1993; 119:370-6.
17. Improving ADR reporting. Lancet. 2002; 360:1435. Editorial.
18. Lata P, VanCourt B, Larson P. Pharmacist as a member of a hospital case management department. Am J Health-Syst Pharm. 2000; 57:2202-6.
19. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
20. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992; 27:538.
21. Genrich SJ, Neatherlin JS. Case manager role: a content analysis of published literature. Care Manag J. 2001; 3:14-9.
22. Schriefer JA, Botter ML. Nurse case management skills required for care management. Outcomes Manag Nurs Pract. 2001; 5:48-51.
23. Saltiel E, Johnson E, Shane R. A team approach to adverse drug reaction surveillance: success at a tertiary care hospital. Hosp Formul. 1995; 30:226-32.
24. Murphy BM, Frigo LC. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. Hosp Pharm. 1993; 28: 1199-204.
25. Etzel JV, Brocavich JM, Rousseau M. Impact of the development of a multidisciplinary adverse drug reaction committee. Hosp Pharm. 1995; 30:1083-7.
26. Keith MR, Bellanger-McCleery RA, Fuchs JE. Multidisciplinary program for detecting and evaluating adverse drug reactions. Am J Hosp Pharm. 1989; 46: 1809-12.
27. Evans RS, Pestotnik SL, Classen DC. Preventing adverse drug events in hospitalized patients. Ann Pharmacother. 1994; 28:523-7.
28. CM can play critical role in reducing medical errors. Hosp Case Manag. 2001; 9:99-100.
29. Davidhizar R, Lonser G. Medication errors: what case managers can do. Hosp Case Manag. 2002; 10:77-80.
30. Morrison P, Meehan T, Gaskill D et al. Enhancing case managers' skills in the assessment and management of antipsychotic medication side-effects. Aust N Z J Psychiatry. 2000; 34:814-21.
31. Forster AJ, Murff HJ, Peterson JF et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138:161-7.